Increased incidence of cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation

Transplantation

Volumn 83, Issue 1, 2007, Pages 80-83

  Xhaard, Aliénor ^a   Robin, Marie ^a   Scieux, Catherine ^a   De Latour, Régis Peffault ^a   Deplus, Sylvie ^a   Mazeron, Marie Christine ^b   Devergie, Agnès ^a   Espérou, Hélène ^a   Rocha, Vanderson ^a   Gluckman, Eliane ^a   Ribaud, Patricia ^a   Socié, Gérard ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

CMV; Retinitis; Transplantation

Indexed keywords

ANTIVIRUS AGENT; BUSULFAN; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; FOSCARNET; GANCICLOVIR; METHOTREXATE; STEROID; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOMEGALOVIRUS; EYE EXAMINATION; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; OPHTHALMOSCOPY; ORGAN DONOR; PRIORITY JOURNAL; RETINITIS; RISK FACTOR; TIME SERIES ANALYSIS; VIRUS REACTIVATION; VISUAL DISORDER;

ADULT; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; CYTOMEGALOVIRUS RETINITIS; DRUG RESISTANCE, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; RETROSPECTIVE STUDIES;

EID: 33846259418     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000239512.94181.e9     Document Type: Article

References (17)

1. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240.
2. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815.
3. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601.
4. Reusser P, Einsele H, Lee J, et al. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159.
5. Martin DF, Sierra-Madero J, Walmsley S, et al. Valganciclovir Study Group. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 1119.
6. Chevret S, Scieux C, Garrait V, et al. Usefulness of the cytomegalovirus (CMV) antigenemia assay for predicting the occurrence of CMV disease and death in patients with AIDS. Clin Infect Dis 1999; 28: 758.
7. Leruez-Ville M, Ouachee M, Delarue R, et al. Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by real time PCR assay performed with blood plasma. J Clin Microbiol 2003; 41: 2040.
8. Ducancelle A, Belloc S, Alain S, et al. Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy. J Clin Virol 2004; 4: 241.
9. Gray RJ. Spline based tests in survival analysis. Biometrics 1994; 50: 640.
10. Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32: 214.
11. Larsson K, Lonnqvist B, Ringden O, Hedquist B, Ljungman P. CMV retinitis after allogeneic bone marrow transplantation: a report of five cases. Transpl Infect Dis 2002; 4: 75.
12. Shapiro S, Robin M, Oudot C, et al. Polyomavirus nephropathy in the native kidneys of an unrelated cord blood transplant recipient followed by a disseminated polyomavirus infection. Transplantation 2006; 82: 292.
13. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101: 407.
14. Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172: 951.
15. Miller GG, Boivin G, Dummer JS, et al. Cytomegalovirus ventriculoencephalitis in a peripheral blood stem cell transplant recipient. Clin Infect Dis 2006; 42: e26-29.
16. Foot AB, Garin YJ, Ribaud P, Devergie A, Derouin F, Gluckman E. Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. Bone Marrow Transplant 1994; 14: 241.
17. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255.